Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

Inclusion Criteria: * Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months * BMI (Body Mass Index) between 24 and 35 kg/m\^2 (both inclusive) * Fasting plasma glucose between 6 and 15 mmol/l (both inclusive) * Anti-GAD (glutamic acid decarboxylase) negative Exclusion Criteria: * Known or suspected allergy to trial product or related products * Receipt of any investigational drug within three months prior to this trial * Recurrent severe hypoglycaemia as judged by the investigator * Cardiac disease or any clinically significant abnormal ECG (electrocardiogram) * Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere * with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides) * Liver or renal disease